XM non fornisce servizi ai residenti degli Stati Uniti d'America.

CVS names Joyner as CEO under investor pressure, withdraws profit forecast



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 6-CVS names Joyner as CEO under investor pressure, withdraws profit forecast</title></head><body>

CVS gives third-quarter outlook below Street estimates

Activist Glenview Capital says CVS board needs 'evolution'

CVS plans to remain as one company under Joyner, sources say

New throughout, adds analyst comment in paragraph 10; sources in paragraph 13, Glenview comment in paragraphs 14-16

By Sriparna Roy and Leroy Leo

Oct 18 (Reuters) -CVS Health CVS.N on Friday replaced CEO Karen Lynch with David Joyner, a CVS veteran who retired before returning to the company last year, after investors including activist Glenview Capital pressured the company to improve its stagnant share price.

It also withdrew its 2024 forecast and gave an outlook for third-quarter earnings far below analyst estimates.

CVS shares were down 7% on Friday. They are down by nearly half from their 2022 highs, in part due to quarter after quarter of repeated profit forecast cuts related to rising costs in its large healthcare insurance business and competition for its vast network of retail pharmacies.

Its third business - pharmacy benefit management - has been profitable but a focal point for U.S. government efforts to bring down U.S. drug prices. The Federal Trade Commission sued it and its rivals last month.

"The board believes this is the right time to make a change, and we are confident that David is the right person to lead our company," CVS Chairman Roger Farah said in a statement.

CVS on Friday said it expected adjusted profit of $1.05 to $1.10 per share for the quarter ended Sept. 30 compared to analysts' estimates of $1.70, according to data compiled by LSEG.

CVS was already growing rapidly beyond its retail pharmacy footprint when it bought health insurer Aetna in 2017, a move it said was needed to try to rein in healthcare costs and as it faced new healthcare competition from Amazon.com and others. In 2021, former Aetna executive Karen Lynch took over as CEO and the company's shares soared as it benefited from its role in the COVID-19 pandemic recovery.

Wall Street analysts have said that the company failed to find the benefits that could come from integration of different acquired businesses.

"This move was brewing for some time, as CVS has struggled under Lynch's leadership following the failed Aetna merger," said Oppenheimer analyst Michael Wiederhorn.

Glenview went public earlier this month with its concerns and sources said a strategic review that could include the split of the company's core businesses was on the table.

In a statement to employees, Joyner, who is on the board of directors, said that in order to succeed the company would need to operate as "one CVS Health."

Two sources familiar with the situation said CVS planned to remain as one company under Joyner.

Glenview said on Friday said that CVS needed to make changes to both leadership and the board.

"We believe the Company's culture, governance and leadership should be strengthened by those with both appropriate industry experience as well as fresh perspectives and that the Company would be best served through prompt Board evolution," it said in a statement.

It said that the company's Medicare insurance division, which accounts for one-third of its business, was "quite fixable."

Costs for insurers providing Medicare plans - available for people aged 65 years and above and those with disabilities - have soared in the last year due to sustained high demand from older adults for healthcare services.

CVS's third-quarter medical care ratio, the percentage of premiums spent on medical care, is significantly higher at 95.2% than estimates of 90.95%. The industry generally targets a medical benefit ratio closer to 80%.

Lynch stepped down from her position in agreement with CVS Health's board, the company said. Joyner, who is the president of the company's pharmacy benefit manager CVS Caremark, takes over as president and CEO from Friday.



Reporting by Leroy Leo and Sriparna Roy in Bengaluru; writing by Caroline Humer; Editing by Maju Samuel, Devika Syamnath and Nick Zieminski

</body></html>

Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.

Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.

Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.

Avvertenza sul rischio: Il tuo capitale è a rischio. I prodotti con leva finanziaria possono non essere adatti a tutti. Ti chiediamo di consultare attentamente la nostra Informativa sul rischio.